CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER (cefoxitin sodium) · B BRAUN
Cefoxitin for Injection and Dextrose Injection is a cephalosporin antibacterial indicated for the treatment of the following infections caused by susceptible isolates of the designated bacteria : Lower respiratory tract infections ; Urinary tract infections ; Intra-abdominal infections ; Gynecological infections ; Septicemia ; Bone and joint infections ; Skin and skin structure infections ; Prophylaxis .
Development Insights
Details
- Status
- Prescription
- First Approved
- 2006-03-10
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER Approval History
What CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER Treats
14 indicationsCEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER is approved for 14 conditions since its original approval in 2006. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Lower Respiratory Tract Infections
- Pneumonia
- Lung Abscess
- Urinary Tract Infections
- Intra-Abdominal Infections
- Peritonitis
- Intra-Abdominal Abscess
- Gynecological Infections
- Endometritis
- Pelvic Cellulitis
- Pelvic Inflammatory Disease
- Septicemia
- Bone and Joint Infections
- Skin and Skin Structure Infections
CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER FDA Label Details
Indications & Usage
FDA Label (PDF)Cefoxitin for Injection and Dextrose Injection is a cephalosporin antibacterial indicated for the treatment of the following infections caused by susceptible isolates of the designated bacteria : Lower respiratory tract infections ; Urinary tract infections ; Intra-abdominal infections ; Gynecological infections ; Septicemia ; Bone and joint infections ; Skin and skin structure infections ; Prophylaxis . To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefoxitin for Injection and Dextrose Injection and other antibacterial drugs, Cefoxitin for Injection and...
Track CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.
How We Calculate These Metrics
Trial Activity Stage
Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.
Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.
- Growth: High proportion of early-phase trials (Phase 1/2), active development
- Expansion: Significant Phase 3 activity, approaching or pursuing approvals
- Mature: Substantial Phase 4 post-marketing studies
- Stable: Mixed phase distribution, steady development
- Declining: Low active trial ratio, reduced R&D investment